| Literature DB >> 26587323 |
Monica Parodi1, Marco Pedrazzi1, Claudia Cantoni2, Monica Averna3, Mauro Patrone4, Maria Cavaletto4, Stefano Spertino4, Daniela Pende5, Mirna Balsamo1, Gabriella Pietra6, Simona Sivori3, Simona Carlomagno1, Maria Cristina Mingari7, Lorenzo Moretta8, Bianca Sparatore3, Massimo Vitale5.
Abstract
In this study we characterize a new mechanism by which Natural Killer (NK) cells may amplify their recruitment to tumors. We show that NK cells, upon interaction with melanoma cells, can release a chemotactic form of High Mobility Group Box-1 (HMGB1) protein capable of attracting additional activated NK cells. We first demonstrate that the engagement of different activating NK cell receptors, including those mainly involved in tumor cell recognition can induce the active release of HMGB1. Then we show that during NK-mediated tumor cell killing two HMGB1 forms are released, each displaying a specific electrophoretic mobility possibly corresponding to a different redox status. By the comparison of normal and perforin-defective NK cells (which are unable to kill target cells) we demonstrate that, in NK/melanoma cell co-cultures, NK cells specifically release an HMGB1 form that acts as chemoattractant, while dying tumor cells passively release a non-chemotactic HMGB1. Finally, we show that Receptor for Advanced Glycation End products is expressed by NK cells and mediates HMGB1-induced NK cell chemotaxis. Proteomic analysis of NK cells exposed to recombinant HMGB1 revealed that this molecule, besides inducing immediate chemotaxis, also promotes changes in the expression of proteins involved in the regulation of the cytoskeletal network. Importantly, these modifications could be associated with an increased motility of NK cells. Thus, our findings allow the definition of a previously unidentified mechanism used by NK cells to amplify their response to tumors, and provide additional clues for the emerging role of HMGB1 in immunomodulation and tumor immunity.Entities:
Keywords: HMGB1; NK cells; chemotaxis; melanoma cells; tumor microenvironment
Year: 2015 PMID: 26587323 PMCID: PMC4635845 DOI: 10.1080/2162402X.2015.1052353
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110